Abstract:Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and beta-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and beta-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve beta-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

Advance in Hepcidin

Hepcidin and Iron in Health and Disease

Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

Hepcidin Signaling in Health and Disease: Ironing Out the Details

Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis

The regulatory roles of hepcidin on body iron homeostasis

Hepcidin: from discovery to differential diagnosis

Physiological and Pathophysiological Mechanisms of Hepcidin Regulation: Clinical Implications for Iron Disorders

Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia

Nuclear Factor-Kappa B Mediated Lipopolysaccharide-Induced Mrna Expression Of Hepcidin In Human Peripheral Blood Leukocytes

Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Hepatic Hepcidin Protects Against Polymicrobial Sepsis in Mice by Regulating Host Iron Status.

Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota

Iron metabolism and iron disorders revisited in the hepcidin era

Induced Disruption of the Iron-Regulatory Hormone Hepcidin Inhibits Acute Inflammatory Hypoferraemia

Airway epithelial hepcidin coordinates lung macrophages and immunity against bacterial pneumonia

Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice

Pgc-1 Alpha Regulates Hepatic Hepcidin Expression And Iron Homeostasis In Response To Inflammation

Hepcidin protects sepsis through regulating iron homeostasis to inhibit immunocyte apoptosis in mice

Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia Through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease